oxbt_fwp.htm

Legal Disclaimer

This Presentation contains forward looking statements which reflect the Company’s plans, goals
and expectations as of this date. All statements other than statements of historical facts which
address the Company’s expectations on such matters as sources of capital, the Company’s plans
for the future with respect to financial performance or operating strategies, can be identified as
forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides a safe
harbor for forward looking information made on the Company’s behalf. Actual results may differ
materially from the expectations expressed in the forward-looking statements. There can be no
assurance that those plans, goals or expectations will be realized. Additional information
concerning these and other risk factors affecting Oxygen Biotherapeutics, Inc.'s business can be
found in the company's public periodic filings with the Securities and Exchange Commission,
which are available via www.oxybiomed.com. Oxygen Biotherapeutics, Inc. disclaims any intent or
obligation to update these forward-looking statements beyond the date of this release. This
caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. This presentation is not an offer or a solicitation of an offer to buy any securities in the
Company.

NASDAQ:OXBT

Free Writing Prospectus Statement

The issuer has filed a registration statement (including a prospectus) with the SEC for the offering
to which this communication relates. Before you invest, you should read the prospectus in that
registration statement and other documents the issuer has filed with the SEC for more complete
information about the issuer and this offering. You may get these documents for free by visiting
EDGAR on the SEC Web site at www.sec.gov. The preliminary prospectus, dated June 27, 2013, is
available on the SEC Web site at:

http://www.sec.gov/Archives/edgar/data/34956/000135448813003663/oxbt_s1a.htm

Alternatively, the issuer, any placement agent or any dealer participating in the offering will
arrange to send you the prospectus if you request it by calling 1-919-855-2120.

NASDAQ:OXBT

Oxycyte® & U.S. Military Development

§ Joint Development with Aurum Biosciences
for Diagnostic for Stroke

§ IV Product: Oxycyte® in clinical
development for traumatic brain injury and
preclinical development for stroke

§ Dermacyte®, Topical Cosmetic Production
outlicensed to Valor Cosmetics which is
currently marketed

Oxygen Biotherapeutics, Inc. is currently developing Oxycyte®, a systemic perfluorocarbon-based
emulsion, that we believe is a safe and effective oxygen carrier for use in several indications.

§ Phase IIb in Traumatic Brain Injury (TBI) ongoing

§ European and Israeli Sites open for Enrollment

§ US Navy Development Relationship

NASDAQ:OXBT

About the Company

Corporate Highlights include:

Lead Product Candidate: Oxycyte® PFC Emulsion

Oxycyte®
Composition	§ FtBu-based oil-in-water PFC emulsion.
Delivery	§ Intravenously, 3mL/kg body weight (~ 9 oz. for average weight person)
Compatibility	§ All blood types (no biological components)
Shelf Life	§ Extended shelf life (metabolically inert)

Mechanism of Action
Healthy Tissue	Injured Tissue & Oxycyte®

Red blood cells travel
through capillaries,
delivering constant
supply of oxygen

Swelling blocks
transport of red blood
cells and impedes
oxygen delivery to
tissue

PFC particles from Oxycyte® transport
oxygen without the need for
erythrocytes and hemoglobin to
perfuse and oxygenate tissue where
capillaries are narrowed.

FtBu

Oxycyte® PFC
Emulsion

Market Opportunities & Indications

Market Opportunities:

Traumatic Brain Injury (TBI)

§ $1.25 billion spent annually on TBI patients in the U.S.

Decompression Sickness

§ Impacts 1,000 U.S. scuba divers each year; Recent U.S. Navy numbers are
not available but the indication is important to Navy researchers funding
the Company’s studies

OXBT’s platform technology addresses the high demand for effective treatments in multiple markets

NASDAQ:OXBT

Indications Developed in Partnerships or Out-licensed:

Stroke

§According to the American Heart Association the cost of treating strokes in the U.S. was $72 billion in 2010 and
is projected to increase to $183 billion by 2030

MRI Scanning Diagnostics

§ Global MRI systems market estimated at $4.2 billion in 2011 and is forecast to reach a total of $6 billion by the
year 2018 according to GBI Research

Cosmetics

§Anti-aging cosmetics is estimated to reach a $9.9 billion market by 2016 in the U.S. according to Mintel

Market Opportunity: Traumatic Brain Injury (TBI)

A primary concern following a TBI event is ensuring that a sufficient supply of oxygen is delivered as soon as
possible to the brain and the rest of the body

NASDAQ:OXBT

§ CDC estimates that 1.7M Americans sustain TBI each year

§ 33% of all injury related deaths are due to TBI in the United States (1) and
it’s the leading cause of death and disability in children and young adults

§ An estimated 5.3 million people are living with a permanent TBI-related
disability

§ 75% of all US military casualties of the Iraq wars are caused by explosive
weaponry resulting in TBIs and blast-induced neurotrauma, according to
the US military

§ Est. $1.25 Billion spent annually on TBI patients in the U.S. (1)

§ Currently, no drug is approved to directly treat any phase of TBI or the
associated medical complications. (1) SOP is to stabilize patient to ready
him/her for surgery

Market Opportunity: Traumatic Brain Injury (TBI)

A primary concern following a TBI event is ensuring that a sufficient supply of oxygen is delivered as soon as
possible to the brain and the rest of the body

NASDAQ:OXBT

§ Following TBI, lower brain oxygenation levels are associated with
increased morbidity and mortality.

§ Current treatments involve administration of O2 through the lungs,
but nothing is available to improve O2 delivery to the brain.

§ Oxycyte® delivers O2 to ischemic tissue without the aid of RBCs

§ Oxycyte® circulates through plasma to perfuse O2-deprived regions
not accessible to RBCs due to damaged capillaries.

§ Only intervention focused on reducing brain damage

Oxycyte®: Phase IIb TBI Trials

Phase II-b study to evaluate the Safety and Tolerability of Oxycyte® in Patients with Severe Non-Penetrating
Traumatic Brain Injury (STOP-TBI)

Primary Endpoints of Study
Safety	Efficacy
§ Measured by the incidence and severity of adverse events and/or significant adverse events. Study will measure: — Thrombocytopenia — Nosocomial Infection — Incidence of Re-bleed	§ Decreased mortality and morbidity determined by brain tissue oxygen tension § Short-term improvement (time to extubation, ICU admission and discharge, neuro outcomes as measured by Glasgow Coma Scale) § Functional outcomes as measured by the expanded Glasgow Outcomes Scale-Extended at Day 30 (or discharge), Month 3 and Month 6

Oxycyte® TBI Clinical Trials
Purpose	§ Assess in severe TBI patients the safety and tolerability of a single infusion of Oxycyte® when used in combination with 50-80% inspired O2 and standard of care practices.
Design	§ Randomized , placebo-controlled, double-blind, single dose, dose escalation study
Location	§ Switzerland and Israel (we expect more locations to be added)
Enrollment	§ 98 Patients (12 in Cohort 1), (18 in Cohort 2), (68 in Cohort 3)
Dosing	§ 1 - 3 mL/kg

NASDAQ:OXBT

STOP- TBI Status & Timeline

Notable Events include:

§ Engaged CRO (Dec 2012)

§ Obtained Approval from Israel Ministry of Health (Jan 2013), Swiss Medic anticipated Feb 2013

§ Initiated first site for 2nd Cohort in Israel in May 2013 (site also participated in 1st Cohort)

Timeline of future events and milestones:

Fiscal 2013

Fiscal 2014

Fiscal 2015

Fiscal 2016

Jan 2013

Apr 2013

Jul 2013

Oct 2013

Jan 2014

Apr 2014

Jul 2013

Oct 2014

Jan 2015

Apr 2015

Jul 2015

Oct 2015

Jan 2016

Engage CRO

Obtain
Regulatory
Approvals

Initiate Sites (8)

Cohort 2 Enrollment (18 Patients)

Initiate Sites (add'l 10)

DSMB

Cohort 3 Enrollment (65 Patients)

Data Collection

DB Lock

NOTE: OXBT fiscal year end is April 30th

Perfluorocarbons and the FDA

§ New and largely unresolved safety-related problems have arisen during the clinical development of
hemoglobin-based (HBOC) and PFC emulsions.

§ The observed toxicities may or may not be clinically significant; however, the mechanisms have not been
fully elucidated.

§ PFCs have two class effects (potential interference with platelet function and immunocompetence) that the
FDA has requested to explore in more detail in order to move forward with the development of Oxycyte® in
the U.S.

§ The following is a list of toxicities thought to be associated with the use of PFC-based therapeutics:

FDA and PFC Development
Toxicity/Lab Finding	Etiology/Physiology	Safety Risk
Thrombocytopenia	Basis for this side effect is not fully understood.	PFCs may lead to changes in the surface characteristics of platelets and subsequent uptake of the altered platelets by the liver and spleen.
Thrombocytopenia	Basis for this side effect is not fully understood.	Platelets may appear "functional" in aggregation but may have a short half-life in circulation
Complement Activation and Cytokine Release	Hypothetical	No data to suggest that complement activation occurs following administration of PFCs.
Reticuloendothelial Blockade	Hypothetical	Administration of PFCs may affect the systems ability to clear circulating bacteria.
"Flu-Like" Symptoms	Unknown	Administration of PFCs has been associated with the development of flu-like symptoms and transient elevations in proinflammatory cytokines.

NASDAQ:OXBT

Addressing the Clinical Hold

OXBT initiated a 2-year preclinical research program fully-funded by a $2.07 million cost- reimbursement
grant from the US Army to address the FDA’s concerns and examine the following:

Oxycyte® and U.S. Army Studies
Study	Detail
Platelet Transfusion	§ Effects of platelet transfusion in treating thrombocytopenia in an intracranial hemorrhage model
Platelet Distribution	§ Platelet distribution in non-human primates with acute systemic inflammation
In Vitro Platelet Function	§ Activation and aggregation studies comparing normal blood vs. traumatic brain injury blood
Immunocompetence	§ Effects of Oxycyte® on bacterial opsonization and resistance to various types of infections

The preclinical program began in July 2011 and is on-schedule to be completed in summer 2013. Results will
be presented to the FDA and disclosed publicly.

NASDAQ:OXBT

Preclinical Safety Studies Status & Timeline

Objectives of preclinical program is to address the FDA’s concerns to that extent that the FDA
hold will be lifted and allow OBI to resume clinical trials in the U.S. with Oxycyte®.

§ OXBT initiated this two-year program in June 2011 and expects all studies to be completed by
summer 2013. Final reports are anticipated in Summer 2013

§ Timeline of events and milestones under the U.S. Army agreement are below:

NOTE: OXBT fiscal year ends
April 30th

Fiscal 2012

Fiscal 2013

Fiscal

2014

FQ1

FQ2

FQ3

FQ4

FQ1

June 2012

FQ2

FQ3

FQ4

FQ1

July 2013

Bioanalytical Assay Development / Validation

*Platelet Transfusion Study in rats

*In Vitro Platelet Function

*PK Studies in rodents

*Immunocompetence Studies in mice

*Platelet Distribution Study in primates

*Bars are start of in-life to delivery of final report

The Company has various research-related structures in place with the U.S. Army and Navy for further
understanding and development of Oxycyte® and its therapeutic potential, with a particular emphasis on
defense-related injuries:

§ The U.S. Army has supported a variety of research studies with many institutions investigating the
therapeutic potential of PFCs

§ OXBT has four Cooperative Research and Development Agreements (CRADAs) in place with the U.S. Navy
in the areas of Decompression Sickness, hemorrhagic shock, TBI and wound healing

Military Research Related to Oxycyte®

NASDAQ:OXBT

OXBT has entered into four Cooperative Research and Development Agreements with the U.S. Navy
to examine potential therapeutic applications for Oxycyte®. Per the CRADAs, OXBT supplies the Navy with
Oxycyte® who conducts the studies. Studies are completed, underway or being planned for:

CRADAs: U.S. Navy

Oxycyte® and U.S. Navy Studies
Indication	Studies
Decompression Sickness (DCS) & spinal cord injury related to DCS	Conducting six studies in three models: rat, porcine, sheep § Treatment of DCS with Oxycyte® (completed) § Safety of PFC before standard hyperbaric oxygen recompression therapy (completed) § Oxycyte® Treatment of Spinal Cord Injury (completed) § Oxycyte® for preservation of systemic oxygenation in hemorrhagic shock (completed) § Platelet changes in DCS subject treated with Oxycyte® (underway) § Cardiovascular changes in DCS subject treated with Oxycyte® (underway)
Traumatic Brain Injury (Planning phase)	§ Safety/efficacy testing of oxygen therapeutics as blood component substitutes for pre-hospital resuscitation from TBI § TBI (percussion injury) with 7 day neurocognitive scoring
Hemorrhagic Shock	§ Intravenous Perfluorocarbons for preservation of systemic oxygenation in hemorrhagic shock (completed) § Preventing Acute Respiratory Distress Syndrome and Preservation of Systemic Oxygenation with and without Hemorrhagic Shock (underway)
Wound (Planning phase)	§ Intravenous delivery of Oxycyte® to treat wounds

NASDAQ:OXBT

Oxycyte® and Improved MRI Scans

Oxycyte® for MRI Diagnostics & Stroke

The Company has a Joint Research Agreement with Aurum Biosciences Ltd. to
develop Oxycyte®-based diagnostic tools (“GOLD”) and therapeutics for acute
ischemic stroke

§Currently conducting a series of preclinical studies to explore whether
Oxycyte® administered while the subject is receiving oxygen therapy allows for
optimization of MRI scans and improved patient outcomes

Research presented at the 2012 Gordon Conference on Brain Metabolism Energy & Blood Flow shows that
Oxycyte® improves imaging of the penumbra following acute ischemic stroke

Figure demonstrates the ability of Oxycyte® to produce strong
MRI signal change relative to baseline image.

Identifying and rescuing compromised but salvageable tissue
would lead to significantly improved patient prognosis and
reduced healthcare costs.

§ GOLD will accurately and safely image penumbra while
simultaneously providing a therapeutic effect by delivering
oxygen through Oxycyte®

§ Oxygen is essential to salvage and maintain brain tissue
function and Oxycyte® is more efficient than blood in
delivering oxygen to stroke-affected tissue.

NASDAQ:OXBT

Technology Out-licensed for Cosmetics

Dermacyte® line of topical cosmetic products contains the Company’s patented PFC technology

§ Passed required safety and toxicity tests in the U.S.; Filed a Cosmetic Product Ingredient Statement (CPIS)
with the FDA

§ Market for oxygen-carrying cosmetics includes anti-aging, anti-wrinkle, skin abrasions and minor skin defects

§ Recently out-licensed the exclusive worldwide rights of Dermacyte® to Valor Cosmetics of Switzerland

§ Now generating licensing revenues while reducing operating expenses associated with the non-core skin
care business

NASDAQ:OXBT

Oxygen Benefits

Oxygen purifies, replenishes, moisturizes, heals
and brings back youth to your skin. Oxygen is
vital for radiant, young-looking skin.

Intellectual Property

OXBT relies on a combination of use, method, therapeutic, delivery and composition patents, patent
applications, trade secrets, and proprietary know-how

§ We own or in-license 8 U.S. and foreign patents

§ Exclusive in-licenses to three fundamental gas transport patent applications that represent the core
technology used in our products and product candidates with an average remaining life of approximately 17
years. We have numerous US and foreign country patent applications pending, including:

o 2 U.S. patents (5,824,703; 5,840,767; 6,167,887), 3 Australian patents (690,277; 722,417; 759,557), & 2
Canadian patents (2,239,170; 2,311,122) pertaining to the use & application of PFCs as gas transport agents
in blood substitutes & liquid ventilation with an avg. remaining life of approx. 5 years;

o Numerous patent applications for treatment of several medical and dermatological conditions such as TBI,
acne, burns and wounds with an average remaining life of approximately 18 years.

Our patent and patent applications include claims covering:

§ Methods to treat certain diseases and conditions and for biological gas exchange;

§ therapies for burn and wound victims;

§ Delivery of oxygenated PFC;

§ Various formulations containing PFC; and

§ Methods and compositions for controlled and sustained production and delivery of peroxide and/or oxygen
for biological and industrial applications.

NASDAQ:OXBT

Equity Facts (as of Jan 31, 2013 unless otherwise noted)

Trading Symbol	NASDAQ:OXBT
Stock Price	$4.48
52 Week Range (5/24/13)	$3.60 - $45.00
Shares Outstanding	2.1 million
Average Daily Volume (5/24/13)	302,553*
Market Capitalization (5/24/13)	$8.58 million
Revenue (TTM)	$1.13 million
Total Debt (MRQ)	$2.69 million
Cash & Equivalents (MRQ)	$829,000
Fiscal Year Ends	April 30th

• Not split-adjusted. The Company implemented a 20-for-1 reverse split of its common stock on
May 10, 2013.

• Data on this slide sourced from Yahoo Finance and OTCMarkets

Michael Jebsen - President, CFO & Interim CEO

§ Served as Senior Internal Auditor, Senior Financial Analyst and Chief Ethics Officer with RTI International, a non-profit
R&D organization serving the health and pharmaceuticals industry with over 2,800 employees in more than 40 countries
from January 2006 to February 2008

§ Served in various auditing roles at Grant Thornton, LLP

§ Master of Science in Accounting from East Carolina University; Certified Public Accountant licensed in North Carolina

Col. Charles L. Pamplin III, M.D., Chief Medical Officer

§ Worked on clinical development of numerous FDA approved drugs

§ Served as Vice President of Clinical Development at King Pharmaceuticals

§ Vice President of Quintiles of Americas Internal Medicine Business Unit

§ Licensed and board certified physician and retired U.S. Army Colonel (Medical Corps), specializing in Internal Medicine,
Clinical Pharmacology, Business Management, and Medical Informatics

§ Contributed to the development of anti-malarial, anti-leishmanial, and chemical defense drugs and devices; developed
prophylactic and therapeutic drug treatments and strategies

§ Received several military awards and honors, including the Legion of Merit, the National Defense Service Medal, and the
Army Achievement Medal among others.

Timothy Bradshaw, Ph.D. - Executive Vice President, Clinical Development

§ Served as Deputy Director of Project Management Office at Talacris Biotherapeutics

§ Extensive experience managing and working in Clinical Operations for the contract research organizations, including PPD,
PharmaLink FHI(Novella)

§ Senior Project Manager at GlaxoSmith Kline collaborating with teams to develop and implement sourcing strategies and
processes for Clinical Operations

§ Ph.D. in Biochemistry from the University of South Carolina, B.S. in Chemistry, Erskine College

Stephanie Anderson - Director of Preclinical Research & Development

§ Served in various capacities in the nonclinical development, CRO management and drug evaluation areas at Inspire
Pharmaceuticals before it was acquired by Merck

§ Research Toxicologist at RTI International from 1989 to 2004

§ B.S. Zoology, North Carolina State University

Key Members of Management

NASDAQ:OXBT

Lt. General Dr. Ronald Blanck - Chairman

§ Served as a medical officer and battalion surgeon in Vietnam, retiring as Lieutenant General and Surgeon General of the
U.S. Army and Commander of the U.S. Army Medical Command

§ Served as Commander of Walter Reed Medical Center and the North Atlantic Region Medical Command

§ Current Chairman of Martin, Blanck & Associates, a federal health services consulting firm based in Virginia

§ Former President of the University of North Texas Health Science Center at Fort Worth

Anthony DiTonno - Director

§ Former President and CEO of Neurogesx Inc., (OTCBB:NGSX) a biopharmaceutical company based in San Francisco where
he successfully led the company through FDA approval of its Quetenza® pain patch.

§ Served as Vice President of Marketing and Sales at Enteric Medical Technologies Inc., which was acquired by Boston
Scientific Corporation (NYSE:BSX) for $50 million.

§ Served as Vice President and General Manager of Oclassen Pharmaceuticals Inc., which was sold to Watson
Pharmaceuticals, Inc. (NYSE:WPI) for $111.6 million.

§ B.S. from St Joseph’s University and Drexel University

Chris Rallis - Director

§ Executive at Pappas Ventures, a life science venture capital firm based in Durham, NC

§ Former President and COO of Triangle Pharmaceuticals, Inc., which was acquired by Gilead Sciences (NASDAQ:GILD) in
January 2003 for approximately $465 million.

§ Participated in 11 equity financings generating gross proceeds of approximately $500 million at Triangle Pharmaceuticals
and was primarily responsible for all business development activities which included a worldwide alliance with Abbott
Laboratories (NYSE:ABT) and the in-licensing of 10 compounds

§ A.B. in Economics from Harvard College and a J.D. from Duke University

Board of Directors

NASDAQ:OXBT

Gregory Pepin - Director

§ Co-founder and Managing Director of Vatea Fund, a principal stockholder of OXBT (12.4% total ownership) and co-
founder of EOS Investment, Ltd, an investment company serving as investment manager to Vatea Fund

§ Served as a financial consultant with Winter and Associes in Paris France, an operating subsidiary of Alma Consulting
Group SAS, a French operational consulting services company with over 1,500 employees in 10 countries

§ Master of Science in Economy Finance and Actuaries from HEC Lausanne in Switzerland

William Chatfield - Director

§ Served as Director of the U.S. Selective Service System, having been nominated by President George W. Bush and
confirmed by the U.S. Senate

§ Has more than 30 years of experience working with executive and legislative branches of the Federal government,
including the Department of Defense, Department of the Interior, and the Civil Aeronautics Board

§ Served as an Intelligence Officer with the U.S. Marine Corps

Board of Directors

NASDAQ:OXBT

Upcoming Investment Catalysts

We are focused on the following objectives:

§ This summer, present preclinical safety study findings to the FDA with the goal to resume human
clinical trials in the U.S. with Oxycyte®

§ Complete 2nd and 3rd Cohorts of current Phase IIb TBI clinical trial with lead product candidate
Oxycyte®

§ Expand intellectual property portfolio by exploring new high-potential therapeutic applications
through third-party research collaborations

§ Actively pursue licensing or co-development agreements in non-core business areas

NASDAQ:OXBT